Page last updated: 2024-11-05

epitestosterone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Epitestosterone: The 17-alpha isomer of TESTOSTERONE, derived from PREGNENOLONE via the delta5-steroid pathway, and via 5-androstene-3-beta,17-alpha-diol. Epitestosterone acts as an antiandrogen in various target tissues. The ratio between testosterone/epitestosterone is used to monitor anabolic drug abuse. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

epitestosterone : An androstanoid that is the C-17 epimer of testosterone. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10204
CHEMBL ID196228
CHEBI ID42534
SCHEMBL ID334193
MeSH IDM0007602

Synonyms (61)

Synonym
BIDD:ER0485
17-alpha-testosterone
androst-4-en-3-one, 17-alpha-hydroxy-
androst-4-en-3-one, 17-hydroxy-, (17-alpha)-
brn 1915396
nsc 26499
androst-4-en-3-one, 17-hydroxy-, (17alpha)-
17alpha-testosterone
17-alpha-hydroxyandrost-4-en-3-one
(17-alpha)-17-hydroxyandrost-4-en-3-one
androst-4-en-3-one, 17alpha-hydroxy-
androst-4-en-3-one, 17-hydroxy-, (17.alpha.)-
isotestosterone
nsc26499
epi-testosterone
epitestosterone
androst-4-en-3-one, (17.alpha.)-
17-epitestosterone
nsc-26499
androst-4-en-3-one, 17.alpha.-hydroxy-
17.alpha.-testosterone
481-30-1
testosterone, cis-
17.alpha.-hydroxyandrost-4-en-3-one
cis-testosterone
17alpha-hydroxyandrost-4-en-3-one
LMST02020051
SMP2_000253
NCGC00091018-01
(17alpha)-17-hydroxyandrost-4-en-3-one
alpha epitestosterone
(10alpha,13alpha,14beta,17alpha)-17-hydroxyandrost-4-en-3-one
17alpha-cis-testosterone
DB07768
BRD-K25836724-001-01-6
(8r,9s,10r,13s,14s,17r)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
chebi:42534 ,
CHEMBL196228
NCGC00091018-02
tox21_111058
dtxcid002329
dtxsid8022329 ,
cas-481-30-1
bdbm50410492
48l726977z ,
unii-48l726977z
epitestosterone [mi]
androst-4-en-17.alpha.-ol-3-one
4-androstene-17.alpha.-ol-3-one
testosterone impurity c [ep impurity]
17.alpha.-cis-testosterone
SCHEMBL334193
MUMGGOZAMZWBJJ-KZYORJDKSA-N
4-androsten-17.alpha.-ol-3-one
17-hydroxyandrost-4-en-3-one, (17.alpha.)-
17alpha-hydroxyandrost-4-en-3-one (epitestosterone)
epitestosterone 1.0 mg/ml in acetonitrile
17a-cis-testosterone
Q416852
17-epi-testosterone
(8r,10r,13s,17r)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one

Research Excerpts

Overview

Epitestosterone is a natural component of biological fluids of several mammals including man.

ExcerptReferenceRelevance
"Epitestosterone is a natural component of biological fluids of several mammals including man. "( Epitestosterone--a hormone or not.
Stárka, L, 1993
)
3.17

Effects

Epitestosterone (ET) has been used as a masking agent and prohibited by the World Anti-Doping Agency (WADA) because its administration will decrease the urinary T/ET ratio, a marker of testosterone (T) administration. Epitest testosterone has been shown previously to counteract the testosterone activity in some experimental models.

ExcerptReferenceRelevance
"Epitestosterone (ET) has been used as a masking agent and prohibited by the World Anti-Doping Agency (WADA) because its administration will decrease the urinary T/ET ratio, a marker of testosterone (T) administration. "( Determination of epitestosterone in human urine by off-line immunoaffinity solid-phase extraction coupled with high performance liquid chromatography.
Chen, HX; Deng, QP; Qiu, S; Sun, CJ; Xu, L; Zhang, XX; Zhou, YL, 2010
)
2.14
"Epitestosterone has been identified as a natural component of biological fluids of several mammals including man. "( Epitestosterone.
Stárka, L, 2003
)
3.2
"Epitestosterone has been shown previously to counteract the testosterone activity in some experimental models. "( The activity of epitestosterone in hormone dependent prostate tumour models.
Hampl, R; Maucher, A; Stárka, L; von Angerer, E, 1994
)
2.08
"Epitestosterone has for a long time been considered as a biologically inactive steroid. "( Plasma levels of epitestosterone from prepuberty to adult life.
Hampl, R; Hill, M; Lapcík, O; Stárka, L, 1995
)
2.07
"Epitestosterone has been demonstrated to act at various levels as a weak antiandrogen. "( Sex- and age-related changes in epitestosterone in relation to pregnenolone sulfate and testosterone in normal subjects.
Hampl, R; Havlíková, H; Hill, M; Stárka, L, 2002
)
2.04

Actions

ExcerptReferenceRelevance
"Epitestosterone plays a role in the control of doping with testosterone, since an arbitrary ratio of testosterone to epitestosterone in urine has been accepted as a marker for testosterone abuse."( Plasma levels of epitestosterone from prepuberty to adult life.
Hampl, R; Hill, M; Lapcík, O; Stárka, L, 1995
)
1.35

Bioavailability

ExcerptReferenceRelevance
" It is reasonable to believe that the genetic variation in testosterone bioavailability may be correlated to varying effects of this androgen, whether it is used for replacement therapy or abused in doping."( Bioavailability of testosterone enanthate dependent on genetic variation in the phosphodiesterase 7B but not on the uridine 5'-diphospho-glucuronosyltransferase (UGT2B17) gene.
Belanger, A; Ekström, L; Guillemette, C; Rane, A; Schulze, JJ, 2011
)
0.37
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves (measured as the ability to release both LH and FSH) showed that biotinylated GnRH (Bio-GnRH) was equipotent with or more potent than unlabeled [D-Lys6]GnRH in parallel cultures."( Cytochemical and cytophysiological studies of gonadotropin-releasing hormone (GnRH) target cells in the male rat pituitary: differential effects of androgens and corticosterone on GnRH binding and gonadotropin release.
Childs, GV; Tibolt, RE, 1985
)
0.27
" The dose-response relationship was a biphasic one."( The effect of epitestosterone on the plasma levels of LH and FSH in ovariectomized immature rats.
Bicíková, M; Hill, M; Kanceva, R; Lapcík, O; Stárka, L, 1993
)
0.65
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
androgen antagonistA compound which inhibits or antagonises the biosynthesis or actions of androgens.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
androstanoidAny steroid based on an androstane skeleton and its derivatives.
17alpha-hydroxy steroidThe alpha-stereoisomer of 17-hydroxy steroid.
3-oxo-Delta(4) steroidA 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency26.16790.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency0.04800.000221.22318,912.5098AID743035; AID743036; AID743040; AID743053; AID743054; AID743063
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency2.39400.000214.376460.0339AID720691; AID720692
pregnane X nuclear receptorHomo sapiens (human)Potency25.11890.005428.02631,258.9301AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency4.54640.000229.305416,493.5996AID743069; AID743075; AID743077; AID743079; AID743080
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency17.23250.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency34.37620.000627.21521,122.0200AID651741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)0.01590.00101.979414.1600AID255211
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Olfactory receptor 51E2Homo sapiens (human)EC50 (µMol)0.00070.00000.07800.5700AID1639697
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
adenylate cyclase-activating G protein-coupled receptor signaling pathwayOlfactory receptor 51E2Homo sapiens (human)
cell migrationOlfactory receptor 51E2Homo sapiens (human)
melanocyte differentiationOlfactory receptor 51E2Homo sapiens (human)
steroid hormone mediated signaling pathwayOlfactory receptor 51E2Homo sapiens (human)
positive regulation of blood pressureOlfactory receptor 51E2Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of smellOlfactory receptor 51E2Homo sapiens (human)
cellular response to fatty acidOlfactory receptor 51E2Homo sapiens (human)
melanocyte proliferationOlfactory receptor 51E2Homo sapiens (human)
positive regulation of renin secretion into blood streamOlfactory receptor 51E2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
nuclear steroid receptor activityOlfactory receptor 51E2Homo sapiens (human)
G protein-coupled receptor activityOlfactory receptor 51E2Homo sapiens (human)
olfactory receptor activityOlfactory receptor 51E2Homo sapiens (human)
signaling receptor activityOlfactory receptor 51E2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
plasma membraneOlfactory receptor 51E2Homo sapiens (human)
early endosome membraneOlfactory receptor 51E2Homo sapiens (human)
intracellular organelleOlfactory receptor 51E2Homo sapiens (human)
plasma membraneOlfactory receptor 51E2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624621Specific activity of expressed human recombinant UGT2B7Y2000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID255211Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881)2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624620Specific activity of expressed human recombinant UGT2B7H2000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID50906Inhibition of mouse constitutive androstane receptor (mCAR) activity at 10 uM was determined as percent remaining activity2003Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
Molecular determinants of steroid inhibition for the mouse constitutive androstane receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (260)

TimeframeStudies, This Drug (%)All Drugs %
pre-199059 (22.69)18.7374
1990's62 (23.85)18.2507
2000's72 (27.69)29.6817
2010's55 (21.15)24.3611
2020's12 (4.62)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.41 (24.57)
Research Supply Index5.67 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index77.88 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (48.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (5.45%)5.53%
Reviews14 (5.09%)6.00%
Case Studies5 (1.82%)4.05%
Observational0 (0.00%)0.25%
Other241 (87.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]